Assessing Xenon Pharmaceuticals Inc.'s XEN1101 for the Treatment of Moderate to Severe Major Depressive Disorder (MDD) with a focus on the NOVA trial data

Executed on:Dec 6, 2023 4:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: UT Austin

Chair and Professor, Department of Psychiatry at The University of Texas at Austin.
Research is focused on the pathophysiology of mood and anxiety disorders and he has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer.
Has published more than 1,000 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.

Interview Goal

To gain expert insights on Xenon Pharmaceuticals Inc.'s XEN1101, a potassium channel modulator, for the treatment of moderate to severe MDD. The objective is to understand its potential impact on the treatment landscape of MDD, its clinical efficacy, safety profile, and future prospects.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.